92809-96-6

Basic information

• Product Name: (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride
• Synonyms: (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride;1-(1H-benzo[d]imidazol-2-yl)-N-methylmethanamine dihydrochloride
• CAS NO: 92809-96-6
• Molecular Formula: C9H13Cl2N3
• Molecular Weight: 234.12562
• Mol File: 92809-96-6.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride(92809-96-6)
• EPA Substance Registry System: (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride(92809-96-6)

Safety Data

• Hazardous Substances Data: 92809-96-6(Hazardous Substances Data)

Usage

Description

(1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride is a chemical compound with the molecular formula C9H13N3.Cl2. It is a salt form of the amine compound (1H-benzimidazol-2-ylmethyl)methylamine, with two chloride ions. (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride is known for its ability to act as a ligand in coordination chemistry and can form complexes with various metal ions. The dihydrochloride salt form of this compound increases its stability and solubility, making it easier to handle in laboratory settings and potentially improving its bioavailability in pharmaceutical applications.

Uses

Used in Pharmaceutical Synthesis:
(1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride is used as a building block in the synthesis and development of pharmaceuticals. Its unique structure and ability to form complexes with metal ions make it a valuable component in the creation of new drugs with potential therapeutic applications.
Used in Organic Chemistry:
In the field of organic chemistry, (1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride serves as a reagent, facilitating various chemical reactions and processes. Its stability and solubility in the dihydrochloride form contribute to its effectiveness and ease of use in laboratory settings.
Used in Coordination Chemistry:
(1H-benzimidazol-2-ylmethyl)methylamine dihydrochloride is used as a ligand in coordination chemistry for forming complexes with different metal ions. This application is crucial for studying the properties and potential uses of metal complexes in various fields, such as catalysis, materials science, and medicinal chemistry.

Upstream product

• 107-97-1 sarcosine 
• 95-54-5 1,2-diamino-benzene 
• 4857-04-9 2-chloromethyl-1H-benzimidazole 
• 60-29-7 diethyl ether 
• 175530-24-2 2-[[N-(tert-butoxycarbonyl)-N-methyl]aminomethyl]benzimidazole 

Downstream Products

• 98997-01-4 2-(methylaminomethyl)benzimidazole 

Relevant articles and documents

BENZIMIDAZOLE COMPOUNDS THAT ARE VITRONECTIN RECEPTOR ANTAGONISTS

The present invention provides compounds having formula (I) wherein n, p, q and r are each independently selected from 0 or 1; a, b, c, and d each independently represents a carbon or nitrogen atom, with the proviso that no more than two of a, b, c, and d are nitrogen atoms; Y and Y' each independently represents 1-4 optional substituents selected from alkyl, alkoxy, halo, -CF3, and -C(O)OH; R, R, R and R are H or specified substituents; R, R, R, R, R, R, R and R are independently selected from H or C1-C3 alkyl; or a biolabile ester thereof, or a pharmaceutically acceptable salt thereof. Also provided are methods of using these compounds for treating vitronectin-mediated disorders, e.g., cancer, retinopathy, artherosclerosis, vascular restenosis, and osteoporosis.

Integrin receptor antagonists

Compounds of formula (I) STR1 wherein A1 is C or N; E is a five- or six-membered heteroaromatic or six-membered aromatic ring optionally substituted by R3 or R4 ; X1 --X2 is CHR1 --CH, CR1 =CH, NR1 --CH, S(O)u --CH or O--CH; X3 is CR5 R5 ', NR5, S(O)u or O; R2 is --OR', --NR'R", --NR'SO2 R'", --NR'OR', --OCR'2 C(O)OR', --OCR'2 OC(O)--R', --OCR'2 C(O)NR'2, CF3 or --COCR'2 R2 '; R3, R4 and R7 are independently H, halo, --OR12, --SR12, --CN, --NR'R12, --NO2, --CF3, CF3 S(O)r --, --CO2 R', --CONR'2, R14 --C0-6 alky-, R14 --C1-6 oxoalkyl-, R14 --C2-6 alkenyl-, R14 --C2-6 alkynyl-, R14 --C0-6 alkyloxy-, R14 --C0-6 alkylamino- or R14 --C0-6 alkyl--S(O)r --; R6 is W--(CR'2)q --Z--(CR'R10)--U--(CR'2)s --V-- or W'--(CR'2)q --U--(CR'2)s -- U and V are absent or CO, CR'2, C(=CR152), S(O)n, O, NR15, CR15 'OR15, CR'(OR")CR'2, CR'2 CR'(OR") C(O)CR'2, CR152 C(O), CONR15, NR15 CO, OC(O), C(O)O, C(S)O, OC(S), C(S)NR15, NR15 C(S), SO2 NR15, NR15 SO2, N=N, NR15 NR15, NR15 CR152, NR15 CR152, CR152 O, OCR152, C$(m)ZC, CR15 =CR15, Het, or Ar, provided that U and V are not simultaneously absent, and W and W' are a nitrogen-containing substituent, and integrin receptor antagonists.

Structural and electrochemical studies of some cobalt (III) complexes of 2-aminomethylbenzimidazole and 2-(N-methylaminomethyl) benzimidazole

A number of mixed-ligand cobalt(III) complexes containing either the ligand 2-aminomethylbenzimidazole (ambi) or its N-methyl derivative, namely 2-(N-methylaminomethyl)benzimidazole (mambi), have been prepared in relatively low yield; in particular, the complexes [Co(ambi)(acac)2] Cl, [Co(ambi)(Clacac)2] Cl, K [Co(ambi)(ox)2], [Co(ambi)2(acac)] (ClO4)2, [Co(mambi)(acac)2] Cl and [Co(mambi)(Clacac)2] Cl (acac = acetylacetonate, Clacac = 3-chloroacetylacetonate, ox = oxalate). The reduction potentials of these complexes have been measured in order to assess whether molecules of this type could be potential redox-activated hypoxic cell selective anticancer agents. The complex [Co(ambi)(acac)2] Cl.4·1H2O was characterized by single-crystal X-ray crystallography: a 19.425(1), b 17.734(1), c 15.979(1) A, β 117.52(1)°, monoclinic, space group C2/c (No. 15).